Inclusion Criteria:

- Any of the following hematologic malignancies: very high risk leukemia, acute
leukemia, chronic myeloid leukemia (CML), lymphoma, multiple myeloma (MM),
myelodysplastic syndrome (MDS)

- Incompatibility at two to three loci (HLA-A, B and/or DR) or a single DR locus of the
unshared haplotype between the donor and recipient

- Life expectancy of at least 3 months

- Satisfactory performance status (ECOG ≤ 2);

Exclusion Criteria:

- Possibility of performing an allogeneic transplant with an HLA (human leukocyte
antigen) matched sibling donor

- Availability of an 6/6 HLA-A, B and DRB1 matched unrelated donor within 2-3 months;

- Pregnancy

- Viral hepatitis (B or C)

- Active serious infectious process

- HIV positivity;

- Systemic dysfunction (cardiac, pulmonary, hepatic and renal) contra-indicating
allogeneic stem cell transplantation

- Prior allogeneic transplantation

- Prior autologous transplantation within twelve months of baseline visit

- Any abnormal condition or laboratory result that is considered by the principal
investigator capable of altering patient condition or study outcome

- Active central nervous system (CNS) disease at baseline

- Participation in a trial with an investigational agent within 30 days prior to entry
in the study

- Malignant cells in circulating peripheral blood (> 25%)

- Other active malignant disease that would severely limit life expectancy